See something missing? Fill out this form to add your event.
Webinar #19 – Correcting Premature Stop Codon Mutations using Anticodon Edited Transfer RNA
- This event has passed.
December 4, 2020 @ 6:30 pm – 7:00 pm
Here are our introductory comments:
Drs. George and Ahern have teamed up to create a treatment that will be useful for many different diseases. They leverage basic biology to create a tool that will “read through” a premature stop within a protein. Who does this help? In fact, many of the Syngap1 pathogenic variants (and pathogenic variants for many diseases) are caused by single-base changes in the DNA that result in premature termination of the protein. The changes that will be targeted by their treatment are called nonsense variants because they do not code for an amino acid at that point, but encode a “stop” instead so that the protein-making machinery stops before synthesizing the complete protein.
Dr. George gives a great overview of the basic biology behind the tRNA read-through concept. Dr. Ahern discusses how a treatment might get delivered with an Adeno-Associated Virus (AAV), and importantly shows that the treatment does not have off-target effects. Dr. Ahern describes the next steps in developing a clinical treatment, including making mouse models with protein-truncating variants to test.
The initial results showing no off-target effects are stunning, are applicable to many genes and many patients.
THIS IS FOR TRANSCRIPT ONLY:
0:02move on to our next
0:04um speakers i think we’re going to have
0:05a tag team of speakers here
0:08um with dr al george and dr
0:11um christopher ahern and so i’ll
0:13introduce them both
0:16and then let them take uh take you can
0:18go ahead and get your slides ready if
0:19you’d like
0:20um so um dr george is the professor andSynGap Research Foundation 2nd Annual SynGAP Roundtable
0:23chair of the department of pharmacology
0:25and director of the center for
0:26pharmacogenomics at northwestern
0:28university school of medicine he
0:30also directs the ninds-funded
0:33channelophasy-associated epilepsy
0:35research
0:36center without walls which was recently
0:39funded and is a large collaborative
0:41effort to
0:43uh catalog mutations and effects of
0:45those mutations in uh
0:46ion channels christopher ahern is a
0:49professor in the department of molecular
0:50physiology and biophysics and a member
0:52of the iowa neuroscience institute
0:54at university of iowa um near and dear
0:57to my heart
0:58i grew up near there um and he has
1:00developed a platform of gene therapy
1:02technology
1:03uh engineering transfer rnas used to
1:05correct premature termination
1:07uh determination codons i think we’re
1:08going to hear a little from both of them
1:10in the next half hour
1:11thank you all right thank you very much
1:13heather and
1:14i want to thank the organizers
1:18particularly mike and hans for inviting
1:21me and allowing me to tag team today
1:24with my friend and colleague chris ahern
1:26from the university of iowa to tell you
1:28a little bit about a conceptual
1:31approach to correcting
1:34a certain class of mutations in syngap1
1:38and these are premature stop codon
1:40mutations and i’ll
1:41give a little bit of an introduction
1:43with some background especially for
1:45members of the audience
1:46who aren’t familiar with the nuances of
1:48molecular biology
1:50and then i’ll turn it over to chris for
1:52him to share with you
1:53his uh brilliant and and elegant
1:56technology for
1:57rescuing stop codons uh premature stop
2:00codons and then i’ll take it back
2:01for just uh some final words about what
2:04we’re cooking up
2:05that could be applied to syngap1
2:08so let me start by just sharing with youGenes to Proteins: Molecular Biology
2:11sort of the big picture
2:12this is what is often referred to as the
2:14central dogma
2:15of molecular biology it’s what we’ve
2:18come to understand
2:19is the flow of genetic information from
2:22the cell which contains
2:24the dna that is transcribed into rna
2:28and then the rna is translated into
2:30protein and certainly anywhere along
2:32this
2:33pathway one can have a genetic mutation
2:35that disrupts the process
2:37and thwarts the effort to make an
2:40important biologically active protein
2:42but today we’re going to focus a lot on
2:44things that disrupt the translation step
2:47and results in incompetent proteins
2:50being made so translation involves
2:54the reading of messenger rna
2:58by an organelle called the ribosome
3:01and ribosomes scan messenger rna
3:05almost like a barcode reader would read
3:07a a
3:08series of barcoded instructions in the
3:11case of the ribosome
3:13the barcode is actually clusters or
3:16groupings
3:17of three nucleotides present in the rna
3:20sequence
3:21and each of these three clusters of
3:23three nucleotides
3:24if read properly in the right sequence
3:27will
3:28code for a specific sequence of
3:31amino acids in a protein and so theTranslation of mRNA Requires Transfer RNAs
3:34process of reading the rna
3:35involves a specialized type of rna
3:38called
3:39transfer rnas that are depicted here
3:41schematically
3:42and these are small very small rna
3:45molecules
3:46that are built to recognize
3:49the bar codes in messenger rna and
3:53couple that recognition with the
3:56coupling
3:56with a coupling of the molecule to an
3:59amino acid
4:01and then the process is directed by the
4:03genetic code
4:04each triplet codon in the mrna sequence
4:07or the barcode
4:09is defines a specific amino acid
4:13so the process of translating mrnaMessenger RNA Directs Protein Synthesis
4:16sequence
4:16into a protein is graphically
4:18illustrated here where
4:20the ribosome docks to messenger rna it
4:23recognizes
4:24a first codon known as the start codon
4:27which codes for methionine residues in a
4:29protein
4:31that allows the cognate transfer rna
4:34to dock to that position and then the
4:37ribosome
4:38scans along and finds the next triplet
4:40spot where
4:42another transfer rna is bound and
4:45eventually you get a
4:46you get a coupling of the two amino
4:48acids that are
4:49placed in close proximity and the
4:51peptide synthesis begins
4:53the process continues sequentially with
4:59as many trnas bound to the mrna as
5:02possible
5:03until the ribosome reaches a signal
5:06which for which there is no there is no
5:09uh
5:10trna coupled to a amino acid and this is
5:13called a stop codon
5:14and so this is the natural process of
5:17generating a polypeptide
5:20there is a class of mutations of course
5:22that introduce
5:23stop codons prematurely in
5:27a messenger rna and unlike the normal
5:30sequence of events
5:31where one reads the mrna and generates
5:34the full length protein which presumably
5:36will be functional
5:38in these disease states where there is a
5:40premature stop codon
5:43the protein can’t be made in its full
5:45length and is either
5:48made in a truncated form which may not
5:50be biologically active
5:52or the messenger rna will undergo a
5:54process called nonsense
5:56mediated mrna decay which will disrupt
5:59it
6:00and you get nothing and unfortunately in
6:02many cases premature stop codons
6:05essentially fork the entire translation
6:07process
6:08and no biologically active protein is
6:10madePremature Stop Codon Mutations in SYNGAP1
6:13now in syngap1 a large fraction maybe
6:16close to half of all the reported
6:18mutations are in fact
6:20premature stop codons and here is simply
6:23a linear
6:24depiction of the syngap protein molecule
6:27with its various domains
6:29and shown as small colored lollipops
6:34at various locations along the protein
6:37are the various stop codon mutations
6:39that have been
6:40reported and these stop codon mutations
6:42may involve
6:43different amino acid coating triplets
6:46in the sequence most commonly are
6:50glutamine to stop codon mutations
6:53and arginine to stop codon mutations but
6:56there are
6:57representatives of very much all of the
7:00possible
7:02stop codon types so if there was a way
7:05to repair these individual mutations
7:09one might be able to allow the
7:10translation process
7:12to continue reading through
7:16that stop codon and not make a truncated
7:18protein but perhaps make the full length
7:20protein which may hopefully be
7:22functional
7:23now there’s been a number of
7:24opportunities or our efforts i should
7:27say
7:27to develop small molecule
7:30therapeutics to try to force
7:33the ribosome to read through a stop
7:36codon
7:37and and those have worked in
7:40the cell systems but i think they’ve run
7:43into trouble when
7:45they’ve been moved toward clinical
7:48applications
7:49and so read through technology driven by
7:52small molecules has not
7:54really earned the respect of
7:58the therapeutic world so one needs
8:00another
8:01strategy to tackle this particular type
8:04of mutation
8:05and this is where the brilliant mind of
8:09my colleague
8:10chris ahern comes in so i’m going toUsing transfer RNA (TRNA) to repair PTC
8:11hand the baton to chris and he’s going
8:13to
8:14explain to you what uh he does after he
8:16unmutes
8:17yeah i’ve unmuted thanks al for that
8:19very elegant introduction to molecular
8:21biology and uh thanks as well the
8:22organizers for letting us
8:24tag team and kind of bring to your
8:26attention this really conceptual
8:28uh level of a therapeutic that we’re
8:31working on at this point to develop and
8:32we’re pointing it towards syngap as well
8:34as
8:34a number of other proteins um so the
8:37premise for the the
8:38the idea that that we have of using
8:40transfer rnas as al discussed
8:43involves this idea from human genetics
8:45that we now know that there are many
8:47different genes for human trnas as many
8:50as 450 different trnas so
8:52as al was showing you know you have a
8:55trna that decodes
8:56a triplet codon there are actually many
8:59different types of trna that can decode
9:00those triplet codons
9:02so for instance with arginine there are
9:04more than 30 different types
9:06of trnas which are unique sequences yet
9:08they all possess
9:10the commonality of decoding an arginine
9:12codon to
9:13an arginine uh in encoding a in a
9:15polypeptide and
9:16so we decided to do is to take advantage
9:18of that biological diversity and
9:20to construct a platform in a biological
9:23screen such that if we could audition
9:26the ability of trnas to tolerate
9:29mutations within this anti-codon loop
9:31that we’re pointing to here on the left
9:33side if
9:34al can run the screen i’m not sure if he
9:36if he wants
9:37yeah so there’s an anticodon region of
9:39the transfer rna
9:41and this is the part that engages into
9:42the mrna
9:44and decodes uh the triplet codon and
9:46then allows for the encoding of
9:47the amino acid and so what we did is we
9:50systematically
9:51altered the anticodons of transfer rnas
9:55such that they would no longer suppress
9:57their cognate amino acid codon
9:59but instead suppress a triplet stop
10:02codon
10:03and we chose the ones that the 10
10:06families of trnas which are uniquely
10:08vulnerable to conversion to stop codons
10:11and so what we did is we changed all
10:13those systematically
10:14to stop codon suppressors depending on
10:16what disease stop
10:18was most relevant and then we built a
10:20screen in
10:21human embryonic kidney cells such that
10:24we had a reporter
10:25a nanoluciferase which is an enzyme and
10:27that enzyme when it’s fully functional
10:30makes a fluorescent substrate and so
10:32what we can do is if we put a stop codon
10:34in that enzyme we can look at the
10:37ability of transfer rnas in human cells
10:40to rescue that stop codon by making the
10:42full length enzyme and thus having a
10:44fluorescent output
10:46with the idea being um that it’s in the
10:48right
10:49environment such that you know we will
10:51be able to then learn more about which
10:53trnas are
10:54are going to be effective for this
10:55conversion and as you may guess
10:57many of them are actually not tolerant
10:58but we were surprised to find that many
11:00actually
11:01are and so we go to the next slideIdentification of Multiple tRNA for PTC Repair
11:04and so this is now i know it’s a data
11:06complex
11:07slide but what you’re looking at here is
11:09by color first
11:11each one of these individual colors are
11:13different families of transfer rna genes
11:16and so this for instance in the upper
11:17left these are glycine trnas so
11:19all those bars are actually looking at
11:22the activity
11:23of those different trnas and on the
11:26bottom it’s a log scale
11:28so what you’re looking at here for each
11:29one of those in each one of these
11:31columns there’s a red dotted line and
11:32that means there’s no activity over
11:34background
11:34for those classes of transfer rnas but
11:37what you can see is for instance in the
11:39glycines and this is a log scale
11:41we have three trnas which successfully
11:43decode
11:44uga stops at over a hundred to a
11:47thousand fold
11:48over background now notably for syngap
11:51arginine
11:52this family of transfer rnas was
11:53actually very tolerant
11:55of being converted into uga uh stop
11:58codon suppressors
12:00the ones that work versus the ones that
12:02do not work is very non-obvious we
12:03weren’t able to predict this outcome
12:05so we really needed to do this full
12:07screen
12:08and so when we look at this entire data
12:10set this is now a platform of transfer
12:12rna
12:13novel sequences within this data set we
12:16have potentially
12:17a genetic repair mechanism for every
12:20known
12:21human premature termination codon within
12:24this library and for many of these
12:26families
12:26we have multiple different transfer rnas
12:29that can be auditioned for their ability
12:31to rescue specific stop codons a note on
12:34the transfer rnas themselves they’re
12:36actually quite small
12:37if it wasn’t obvious for males talk
12:38they’re about 75 to 80 bases
12:41so in terms of payload for aav we can
12:43fit multiple
12:44transfer rnas within in within a payload
12:47and also
12:48they don’t really rely on promoters in
12:50the classical sense that we would
12:52normally be driving a gene
12:53expression they just have a small maybe
12:5575 base per liter sequence
12:58so the whole kind of deliverable unit as
13:00it were is really quite compact
13:02and so the idea of uh you know what can
13:06be delivered
13:06we have a a really a a good kind of
13:09buffet
13:10of genetic material that that can be
13:12brought in and what we’re doing here is
13:14is
13:14what we do is we would essentially
13:16convert
13:18the stop site back to its cognate amino
13:20acid and
13:21really making a wild type protein and
13:24this will be based on the
13:25mrna itself that’s being expressed in
13:28the cell so there’s no chance for up
13:30regulation
13:31uh of the member of the protein that’s
13:32being expressed which is a big thing we
13:34worry about in ion channels where
13:36which is where my main expertise is but
13:38also that we know that we’re making at
13:40the end of the day a wild type protein
13:42so then the main concern that we have
13:44going forward is you know what about
13:46real stops and i’ll get to that in a
13:47second but
13:48what i’d like to just kind of show you
13:49uh in the meantime is you know seeing is
13:51believing
13:52and so what i’d like to share with you
13:53is just what do these transfer rnas look
13:55like in terms of syngap mutations and so
13:57we’ll
13:58go to the next slide and so what we didEngineered tRNAs for Common SYNGAP1 PTC
14:01is we took
14:02some of our trnas out of our library and
14:04we’re looking at gfp now and so we put
14:06different stop codons into gfp and we
14:08looked at
14:08we could rescue them so on the left we
14:10have an image of wild-type gfp
14:12transfected into hek cells
14:14when you throw a stop codon in there uh
14:17the cells are fine
14:18as you can see on the left but they have
14:19no fluorescence because gfp has been
14:21terminated
14:22so now all we do is if we co-express one
14:25of our trnas from our library in this
14:27case we we pulled out i believe
14:28it’s an arginine or is it a glutamine so
14:30in this case it was one of our top
14:31performing arginine trnas
14:33and all we need to do is co-express this
14:35arginine trna
14:37and we rescue almost near wild-type
14:39levels of gfp
14:41and hex cells and so the same can be
14:43shown i think we have some glutamine
14:45data
14:45um that we also did yep and so here’s
14:47some glutamine data
14:48where just all we do is we co-express
14:50this as a different stop codon this is
14:52the amber stop tag or uag and rna
14:54language
14:55so we can rescue this glutamine
14:57completely or
14:58really well close back to wild type
15:00levels and so what we have here is a
15:02as a library or a platform to to rescue
15:05but the most important thing we need to
15:06convince ourselves about are off target
15:08effects
15:09every protein as al showed ends with the
15:12real stop
15:12and we don’t want to read through those
15:14real stop codons because that would
15:15cause systematic
15:17uh elongation of the proteome and that
15:19would be very bad in a biological
15:21sense or therapeutic and so we wanted to
15:23do is we wanted to look at
15:25the the read through of real stop codons
15:27and and to do that
15:28we turned to a method called ribosome
15:30rhymosomal profiling
15:32assay and so with ribosomal profilingAssessing Read-through of Real Stops: Ribosomal Profiling
15:34what you do
15:36is you can actually monitor where all
15:37the ribosomes those little organelle
15:39units that al was describing in the
15:40beginning of the talk
15:41all those different ribosomes they’re
15:43scanning rna throughout the entire cell
15:45thousands of transcripts
15:47many different ribosomes sitting on that
15:49rna
15:50and what you can do is if you isolate
15:52that rna from a cell
15:54you can then cleave away all the areas
15:55where there’s no uh
15:57ribosomes and then sequence that little
15:59bit that footprint
16:00where the ribosome is sitting and then
16:02you can get an assay of
16:03where else are all these ribosomes with
16:06the hypothesis that if we’re
16:08reading through real stop codons you’d
16:10start to see
16:11ribosomes showing up after the three
16:14prime stop
16:15and so this is just a summary of the of
16:16the data from human embryonic kidney
16:18cells
16:19over expressing a variety of different
16:21trna suppressors
16:23and what you can see is a sawtooth
16:24activity is essentially um
16:26the ribosome hopping down the end of
16:28these transcripts and these are all the
16:30transcripts lined up
16:31bioinformatically from these cells and
16:33you can see they’re hopping down the the
16:35last codons
16:36of their reading frames and then they
16:38start to slow down near the stop site
16:40and then they
16:40fall off and in the presence of these
16:43trnas
16:44you see no evidence of significant
16:46read-through of any kind
16:47at these real stop codons and i’d love
16:49to there’s some mechanistic reason why
16:51this
16:51is taking place we think but i don’t
16:53really have time to go into it for the
16:54purposes of brevity of this talk
16:56we can also look at this data another
16:58way um if you go to the next slide
17:00so this is then just again looking at
17:02the the read-through of these
17:04these five different high-performing
17:05trnas as well as a read-through drug at
17:08a low
17:08concentration and what we’re looking at
17:10is read-through of different types of
17:12stop codons
17:13with these different types of trnas and
17:14again we really don’t see much evidence
17:17statistically of
17:18read-through of real stop codons and
17:20that really agrees with our observations
17:22in the lab
17:22where we’ve never seen either if we over
17:24express these trnas and many different
17:26uh cell types as well you know hex cells
17:28we’re now in neurons
17:30they’re really well tolerated uh across
17:32the board
17:33um and so uh the last thing i want to be
17:35able to show you um before i go back to
17:37al is
17:38specificity of encoding um because youHigh Fidelity Rescue of PTC by tRNA: Correct amino acid insertion and stop site
17:41know with ion channel proteins in many
17:42uh uh genes uh neuronal genes you really
17:46need specificity missense mutations
17:48can be as deleterious as nonsense
17:50mutations in many instances and that’s
17:52very much true in the ion channel world
17:54as well as for syn gap and in those
17:55small molecules that i’ll mention
17:57they haven’t really gained traction uh
17:59therapeutically
18:00and one reason for that is they put the
18:02wrong amino acid in so they cause this
18:04ribosomal skipping
18:05but they introduce a missense at the
18:07stop site and so what we wanted to do is
18:09just to take a little peek at
18:10what are these trnas encoding at the
18:13stop sites and so that’s what this data
18:14on the left and figure in panel a is
18:17this is mass spec data this is basically
18:19we can purify
18:20protein a test protein in this case out
18:22of a hex cell that’s been rescued
18:24and we can ask whether or not in one
18:26case we put a a
18:28glycine in that’s the middle panel on
18:29the left or a tryptophan and the masses
18:32work out to be identical to what you
18:33would expect
18:34for correct encoding this is now an area
18:36that we’re going into but
18:38the fidelity of the trna the ability to
18:40suppress
18:41the right amino acid and and put the
18:43right amino acid back where it’s
18:44supposed to be
18:45is intact so that’s a very important
18:47aspect but that’s something that will
18:48need to be tested on a case by case
18:50basis as we go look at different genes
18:52but it looks like the fidelity is there
18:54we’re not hitting real stops and we’re
18:55also getting the right amino acid in
18:57if we look at panel b here um what we’ve
19:00been able to do is just
19:01look at are we hitting the right stop
19:02codon right so we then we put different
19:05stop codons
19:05in this luciferase gene and when we
19:08recode this
19:09glycine trna to suppress ugas it
19:12suppresses ugas
19:14even and then in panel c when we compare
19:16this to
19:17some of these read-through drugs even if
19:20you can guess that they’re working maybe
19:21a little bit
19:22so we have gentamicin there we have a
19:23little bit of rescue g418 is an
19:25experimental compound
19:26but then even compared to these trnas
19:28it’s not even close
19:30so the trnas that do a much better job
19:32of suppressing
19:33they put the right amino acid in and so
19:35as in terms of like a biological vector
19:38we think they have a lot of promise for
19:39stop codons because as i was mentioning
19:42there’s a lot of different you know
19:44positions architecturally within
19:46syngap they’re all different they have
19:47all different contexts they’re all
19:48different amino acids
19:50and we don’t necessarily need to
19:51completely understand the complex
19:52molecular genetics and physiology of
19:54syngap
19:55to know that they all share a common
19:57mechanistic basis for the dysfunction
19:59and we see this as a potential way to at
20:01least start rescuing some of these top
20:03codons
20:04and so with that i’ll go back to alRescuing SYNGAP1 PTC by tRNA
20:12thank you chris um so i think just in
20:14the last couple of minutes i’ll just
20:16share with you
20:16kind of the vision that we have going
20:19forward
20:20to apply this technology to syngap1
20:23the premature stop codon so again i
20:25showed this before
20:26this is simply a linear map of the
20:28protein showing its various domains
20:31uh decorated by the location
20:35of various stock codons the two that we
20:37think would be most
20:38uh valuable to target first would be the
20:41arginine
20:42to stop and the glutamine to stop given
20:45that they represent
20:46more than 60 65 percent of all known
20:50uh syngap1 mutation premature
20:53mutation types uh in in the gene uh so
20:56we envision
20:57producing uh eight different syngap
21:00mutations
21:02for arginine and four glutamine to stop
21:04codons express them in hex cells
21:06and then use the trna technology
21:09to see if we can’t rescue them and the
21:12readouts that we’ve envisioned will be
21:14simply can we restore
21:16the synthesis of folding syngap protein
21:19in the cells
21:21using immunoblots to assess that and if
21:24that’s possible maybe we can also
21:26demonstrate using an enzymatic activity
21:28assay the restoration of rask gap
21:32enzymatic activity um and then as chris
21:34wright
21:35highlighted it’s important to
21:36demonstrate the fidelity
21:38of the repair that the stop codon has
21:41been rescued with the correct amino acid
21:44and for that proteomic analysis can be
21:46done and then lastly to make sure that
21:48the
21:49native stop codon isn’t read through
21:51this
21:52ribosome footprinting strategy is what
21:54we have in mind
21:55these are in vitro experiments in
21:57heterologous cells
21:59the natural next step would be to use uh
22:01also
22:02heterologous in v sorry in vitro
22:04experiments but to use
22:06neurons and so to derive human neurons
22:08as dr
22:09koba had explained one can use ips cell
22:12technology
22:13which we do routinely in my lab to
22:14generate both cortical excitatory and
22:16cortical inhibitory neurons
22:19and so we’ve imagined generating these
22:21neurons from patient-derived
22:23uh ips cells that have premature stop
22:26codon mutations in syngap1
22:29and i’m grateful to some members of the
22:32field who’ve actually offered
22:33to share with us some of the existing
22:36cell lines that would
22:38be valuable in this regard
22:42chris’s lab engineers had no associated
22:45virus with
22:46multiplexed tr recoded trnas
22:50that can be engineered to go into
22:52neurons and then again the neurons could
22:54be in
22:55interrogated with immunoblot strategies
22:57to see if
22:58full length syngap protein’s been
23:00restored maybe functionally
23:02and also importantly to look at neuron
23:05morphology and culture
23:07with and without the rescue trna uh then
23:10last but not least of course if the in
23:11vitro experiments were
23:13successful one would want to go in beach
23:15in bevo
23:16and so uh for this we would have to
23:18engineer a mouse
23:19with the corresponding premature stop
23:23codon mutations
23:24none of these are in existence at the
23:26moment and then if that was available
23:28we’d certainly want to try
23:30to do in vivo delivery using aav
23:34viral technology to deliver the trnas to
23:36the mouse brain
23:38and again assess restoration of syngap
23:40active
23:41protein and maybe enzymatic activity if
23:43possible ultimately
23:45the goal long term is perhaps to try to
23:48demonstrate
23:49behavioral rescue and mutant mice so
23:51that’s a long
23:53long term goal which i think we’re not
23:54going to be there anytime soon butAcknowledgements
23:57with that i just want to thank people in
23:58my lab that are
24:00queued up and already actively working
24:02on this technology
24:03applied to ion channels in collaboration
24:05with dr ahern
24:07and to acknowledge dr ahern’s team and
24:09also some collaborators that we’ve
24:11engaged with recently to try to get some
24:13of this work funded
24:14so with that i again thank the
24:17organizers and uh
24:18thank you for your attention
24:22great thanks to both of you i think
24:24that’s actually really exciting
24:27um we have a thank you not a question in
24:30the q a at the moment uh
24:32hans had a question in the chat actually
24:35that said would it be useful uh a useful
24:38study to determine which premature
24:40truncation codons would be targeted for
24:42nmda and which would avoid nmd
24:45or do we have data that tells us
24:47something about it yeah so i think you
24:48know there’s a there’s sort of a general
24:50dogma
24:51that nmd is engaged for
24:54premature stop codons uh throughout
24:57most of the coding region of most genes
25:00except when you get into the last exon
25:03and you’re very close to the tail end of
25:05the
25:06protein coding region and so that’s the
25:08general dogma
25:10certainly one would want more specific
25:14gene-specific information before
25:17tackling this project and i think that
25:19would be something that would be worth
25:20worth doing right now i don’t have any
25:23of that information
25:24at my disposal but it’s a good question
25:26yeah but and also just to add to what al
25:28was saying and also for the
25:30to address the question is it’s our
25:32working hypothesis
25:33at the moment that the the the activity
25:36of these engineer transfer rnas would
25:38actually antagonize
25:39nonsense mediated decay because we think
25:42that they’re going to infer
25:43interfere with the regulation and the
25:45clientele of nmd proteins that
25:47already recognize those stops and so by
25:49having
25:50this trna present we we’re hoping that
25:53actually will
25:53increase the amount of mrna that’s
25:55present as well but again that’s
25:56something that we don’t have access to
25:58any of that information right now
25:59and so for us the syngap is is a really
26:02a great test protein
26:03to start to look at that because as al
26:05said there’s a there’s a dogma out there
26:06but i think we’re in a position to start
26:08to really
26:09uh test that yeah yep
26:12okay two uh quick questions before we
26:14move on um thanks
26:16for the uh let’s see uh clever
26:19intriguing strategy i’m hoping you can
26:20talk a bit more
26:21about why there isn’t more read through
26:24of real thoughts
26:25isn’t there concern that reads through
26:26even a small subset of targets could
26:28have
26:28important biological consequences yeah
26:31sure um so read through happens actually
26:33normally the the
26:34the body is equipped to deal with
26:36read-through that happens at a few
26:37percent all the time
26:39under normal situations um so there’s a
26:41there’s a couple different reasons why
26:43retro doesn’t happen
26:44that’s because the premature termination
26:45codon is in a really different
26:47environment
26:48uh in terms of the nucleotides that
26:49surround it compared to the evolutionary
26:51uh
26:52footprint of a real stop codon which
26:54itself has a clientele
26:56of proteins these uh stop codon binding
26:59proteins ef1 and ef one
27:01or the or sorry the release factors that
27:04bind
27:05to real stop codons and derail ribosomal
27:07translation
27:08premature termination codons don’t have
27:09that so we think that they’re much more
27:10vulnerable to trna suppression
27:12real stops have a whole protection
27:14mechanism built in that keeps
27:16read through from happening but even
27:18though retro happens at a small level
27:20uh most cells are equipped to to deal
27:22with that small amount of stress so
27:24we’re hoping that we can hit the sweet
27:25spot between those two uh
27:27mechanisms and and currently it seems
27:29like we were able to
27:30to hit that that window again everything
27:33is is a therapeutic window
27:35so you know that that will come down to
27:37testing this this platform that we have
27:39we have multiple different trnas um for
27:42any family so
27:43we can then sample if there are ones
27:44that do tend to read through real stops
27:46more than others we haven’t seen that
27:48but if we do we have other ones we can
27:49fall back on uh so
27:51we’re looking forward to getting into
27:52that work absolutely
27:54great and then last question um from
27:57dave you protect
27:58predict that the ptvs will have the same
28:00phenotypes in mouth
28:02surprising there aren’t these patient
28:04type models yet
28:05and then she notes that her son has a
28:08single nucleotide deletion resulting in
28:10a stop
28:10without a frame shift and is it possible
28:14to engineer a compensatory
28:16frame shift into the trna yes i can
28:19tackle that i mean
28:20certainly it is i mean it’s not that
28:23surprising that there’s not
28:24a premature stop codon mouse model at
28:27this point i think
28:28to model haploid sufficiency uh
28:31of syngap1 it was logical to do just a
28:34global knockout
28:35of of the gene and that that i think has
28:38been done
28:39um you know so i think that’s not that
28:41surprising
28:42the the other part of the question is
28:44about the frame shift and unfortunately
28:46frame shift mutations disrupt the
28:49ribosomes ability to
28:51to to capture the right barcodes
28:54uh because they’re the frame the reading
28:56frame has been just
28:57distorted this technology that we talked
29:00about today would not
29:01correct that and i don’t believe that it
29:04would be
29:05valuable to correct a stop codon that’s
29:08in the wrong reading frame because you
29:10might read through
29:11and make a protein sequence that’s not
29:14natural so this technology would only
29:16work for in-frame
29:20premature stop codon mutations
29:24great thank you both um i think that is
29:27a really intriguing study and uh hopeful
29:30step forward
29:30for syngap1 potential therapy